Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO-B) Current Deferred Tax Assets (2009 - 2012)

Bio-Rad Laboratories (BIO-B) reported Current Deferred Tax Assets of $57.8 million for Q4 2012, up 7.39% year-over-year from $53.8 million in Q1 2012, and up 7.39% on a QoQ basis from $53.8 million in Q4 2011.

Bio-Rad Laboratories (BIO-B) has 4 years of Current Deferred Tax Assets data on file, last reported at $57.8 million in Q4 2012.

  • Quarterly Current Deferred Tax Assets rose 7.39% year-over-year to $57.8 million in Q4 2012, while the trailing twelve-month figure through Dec 2012 was $57.8 million (up 7.39% YoY) and the FY2012 annual result came in at $57.8 million, up 7.39% from the prior year.
  • Current Deferred Tax Assets improved to $57.8 million in Q4 2012 per BIO-B's latest filing, from $53.8 million in the prior quarter.
  • Across five years, Current Deferred Tax Assets topped out at $57.8 million in Q4 2012 and bottomed at $43.1 million in Q4 2009.
  • The 4-year median for Current Deferred Tax Assets is $50.9 million (2010), against an average of $50.7 million.
  • The widest annual swing landed in 2011, when Current Deferred Tax Assets climbed 11.99%; it then rose 7.39% in 2012.
  • Tracing BIO-B's Current Deferred Tax Assets over 4 years: stood at $43.1 million in 2009, then grew by 11.41% to $48.0 million in 2010, then rose by 11.99% to $53.8 million in 2011, then gained by 7.39% to $57.8 million in 2012.
  • Per Business Quant, the three latest BIO-B Current Deferred Tax Assets figures stand at $57.8 million (Q4 2012), $53.8 million (Q4 2011), and $48.0 million (Q4 2010).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Bio-Rad Laboratories - - 309.40 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2012 57.75 Mn
Dec 31, 2012 57.75 Mn
Dec 31, 2011 53.78 Mn
Dec 31, 2011 53.78 Mn
Dec 31, 2010 48.02 Mn
Dec 31, 2010 48.02 Mn
Dec 31, 2009 43.10 Mn
Dec 31, 2009 43.10 Mn